4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration on March 15, 2027. There are 7 upcoming events on record.
Cash runway is approximately 15.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| March 15, 2027 | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | Trial Milestone | Phase 1/Phase 2 |
| May 26, 2027 | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia | Trial Milestone | Phase 1 |
| June 15, 2027 | 4D-710 in Adult Patients With Cystic Fibrosis | Trial Milestone | Phase 2 |
| June 15, 2027 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Trial Milestone | Phase 3 |
| November 15, 2028 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Trial Milestone | Phase 3 |
| January 15, 2029 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | Trial Milestone | Phase 3 |
| February 28, 2029 | 4D-150 in Patients With Diabetic Macular Edema | Trial Milestone | Phase 2 |
Track FDMT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open FDMT in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.